Detalhe da pesquisa
1.
Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM.
Bone Marrow Transplant
; 59(5): 660-669, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38383715
2.
The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.
Ther Adv Hematol
; 13: 20406207221082043, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35465644